§ Research summary · Dermal

Melanotan I 10 mg

Also known as · MT-1 · Afamelanotide · Nle⁴-D-Phe⁷-α-MSH

Dermal·1 min read·reviewed 2026-05-07

Afamelanotide — linear α-MSH analogue with enhanced metabolic stability. Approved clinically for a rare photosensitivity indication.

Chemistry quick-facts

CAS
75921-69-6
Formula
C78H111N21O19
MW
1646.87 Da
Length
13 aa
Status
Afamelanotide (MT-1) is approved by the EMA and FDA for erythropoietic protoporphyria (EPP) under the trade name Scenesse®. Omega Grade supplies research-grade peptide only.
Purity (HPLC)
≥ 99.0%

Mechanism of action

Selective agonism at MC1R. Stimulates eumelanogenesis in epidermal melanocytes.

Research context

Afamelanotide (MT-1) is a synthetic 13-amino-acid linear analogue of α-MSH. The Nle⁴ and D-Phe⁷ substitutions confer resistance to enzymatic degradation.

The clinical product Scenesse® (subcutaneous implant) is approved in the EU and US for the prevention of phototoxicity in adults with erythropoietic protoporphyria (EPP).

Omega Grade supplies lyophilised research-grade peptide — not the clinical implant formulation.

Published studies

A non-exhaustive list of peer-reviewed studies referenced when curating this entry. Click through to the primary source for the full text.

  1. Langendonk JG, Balwani M, Anderson KE, et al. (2015). Afamelanotide for Erythropoietic Protoporphyria. New England Journal of Medicine.

Reconstitution

Solvent
Bacteriostatic water for injection (0.9% benzyl alcohol) — included with kit
Typical volume
1 – 2 mL
  • · Inject diluent slowly down the side of the vial onto the cake.
  • · Swirl gently — do not shake.
  • · Solution should be clear and colourless. Discard if not.

Storage

Lyophilised
−20 °C, desiccated, protected from light. Stable at 15–25 °C for up to 30 days in transit.
Reconstituted
2–8 °C, original vial, consumed within 4 weeks.
Shelf life — sealed
24 months from date of manufacture when stored lyophilised at −20 °C.

FAQ

What is the difference between MT-1 and MT-2?+

MT-1 (afamelanotide) is a linear, MC1R-selective analogue that reached clinical approval for EPP. MT-2 is a cyclic, non-selective melanocortin-receptor agonist for research only.

Research-use disclaimer

This page summarises the research literature on Melanotan I 10 mg for in vitro laboratory investigation only. It is not medical advice, not a treatment recommendation, and not a substitute for a qualified physician. Material is sold for analytical chemistry and cell-culture research, not for human or veterinary administration.

View Melanotan I 10 mg in the catalogue →
§ Related reading